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In Brief
Bowry et al. show that BET inhibitors,
emerging cancer therapeutics that target
transcription programs, cause conflicts
between transcription and replication by
deregulating P-TEFb. These conflicts
recruit the homologous recombination
factor RAD51, which slows down
replication and suppresses DNA damage.
This highlights the importance of
replication stress for BET inhibitor
treatment.
Cell Reports
ReportBET Inhibition Induces HEXIM1- and RAD51-Dependent
Conflicts between Transcription and Replication
Akhil Bowry,1 Ann Liza Piberger,1 Patricia Rojas,1 Marco Saponaro,1 and Eva Petermann1,2,*
1Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
2Lead Contact
*Correspondence: e.petermann@bham.ac.uk
https://doi.org/10.1016/j.celrep.2018.10.079SUMMARY
BET bromodomain proteins are required for onco-
genic transcription activities, and BET inhibitors
have been rapidly advanced into clinical trials. Un-
derstanding the effects of BET inhibition on pro-
cesses such as DNA replication will be important
for future clinical applications. Here, we show that
BET inhibition, and specifically inhibition of BRD4,
causes replication stress through a rapid overall in-
crease in RNA synthesis. We provide evidence that
BET inhibition acts by releasing P-TEFb from its
inhibitor HEXIM1, promoting interference between
transcription and replication. Unusually, these tran-
scription-replication conflicts do not activate the
ATM/ATR-dependent DNA damage response but
recruit the homologous recombination factor
RAD51. Both HEXIM1 and RAD51 promote BET in-
hibitor-induced fork slowing but also prevent a
DNA damage response. Our data suggest that
BET inhibitors slow replication through concerted
action of transcription and recombination machin-
eries and shed light on the importance of replication
stress in the action of this class of experimental
cancer drugs.
INTRODUCTION
Members of the BET bromodomain-containing protein family
bind to lysine-acetylated histone tails and regulate transcription
by recruiting and activating positive transcription elongation
factor b (P-TEFb). P-TEFb can occur in two active complexes
with BET protein BRD4 or the super elongation complex (SEC)
and an inactive complex with 7SK-snRP (7SK RNA, HEXIM1,
LARP7, and MEPCE). BRD4 activates P-TEFb by releasing it
from 7SK-snRP and recruits active P-TEFb to gene promoters
(Quaresma et al., 2016). Active P-TEFb facilitates RNA polymer-
ase II (Pol II) pause release by phosphorylating the RNA Pol II
C-terminal domain (CTD) and other targets.
BET proteins promote oncogenic transcription programs,
and specific small-molecule inhibitors of BET bromodomains
promise a targeted cancer treatment (Delmore et al., 2011).
BET inhibition downregulates MYC protein levels and kills tu-
mor cells independently of p53 (Da Costa et al., 2013). In solidCell Repor
This is an open access article undtumor cells, BET inhibitor responses can be MYC independent
(Lockwood et al., 2012). Although the molecular mechanisms
surrounding BET inhibitor action are still poorly understood,
BET inhibitors are already undergoing clinical trials in a wide
range of cancers (Andrieu et al., 2016; Fujisawa and Filippako-
poulos, 2017).
More recently, BRD2 and BRD4 have been implicated in
DNA replication and DNA damage responses (Da Costa
et al., 2013; Floyd et al., 2013; Sansam et al., 2018). BRD4
in particular interacts with DNA replication factors RFC,
TICRR, and CDC6 (Maruyama et al., 2002; Sansam et al.,
2018; Zhang et al., 2018). Inhibiting the interaction between
BRD2/4 and TICRR slowed euchromatin replication, suggest-
ing that BET proteins control DNA replication initiation to pre-
vent interference between replication and transcription (San-
sam et al., 2018). BET inhibitors cause little or no DNA
damage but promote downregulation of DNA replication
stress-response and stress-repair genes (Pawar et al., 2018;
Zhang et al., 2018). It is not known whether the latter are spe-
cific responses to BET inhibition affecting replication and
repair. Investigating more direct effects of BET proteins and
BET inhibition on DNA replication might help understand BET
inhibitor action independently of cell-type-specific transcrip-
tion programs and provide insights into potential side effects
and resistance mechanisms.
We previously reported that JQ1 treatment slows replication
fork progression in NALM-6 leukemia cells, indicative of replica-
tion stress (Da Costa et al., 2013). Replication stress occurs
when the transcription machinery or other obstacles hinder repli-
cation fork progression, which promotes formation of mutagenic
or cytotoxic DNA damage, especially double-strand breaks
(DSBs). This is highly relevant to cancer therapy, as many con-
ventional chemotherapies act by causing severe replication
stress and collapse of replication forks into DSBs. However,
non-toxic levels of replication stress can promote genomic insta-
bility, an unwanted side effect of cancer therapy (Kotsantis et al.,
2015).
Here we describe a mechanism by which BET inhibition
causes replication stress. We show that BET inhibition and
loss of BRD4 cause rapid upregulation of RNA synthesis and
transcription-dependent replication fork slowing in a pathway
that depends on HEXIM1 and RAD51. Unexpectedly, combina-
tion of BET inhibitor with HEXIM1 or RAD51 depletion prevents
fork slowing but activates a DNA damage response, suggesting
that replication fork slowing might help suppress BET inhibitor-
induced DNA damage.ts 25, 2061–2069, November 20, 2018 ª 2018 The Author(s). 2061
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
RESULTS
U2OS osteosarcoma cells were used as a well-characterized
model for replication stress and DNA damage. Osteosarcoma
is one of many cancers proposed to benefit from BET inhibitor
treatment (Lamoureux et al., 2014). We confirmed that JQ1 treat-
ment slowed replication within 1 hr (Figures 1A and 1B). Replica-
tion was also slowed by lower concentrations of JQ1 and
another BET inhibitor, I-BET151 (Figures S1A and S1B).
As reported previously (Da Costa et al., 2013), replication forks
speeds were recovered to control levels after 24 hr incubation
with JQ1 and remained at control levels for up to 72 hr (Fig-
ure S1C). This was not due to loss of JQ1 activity, because add-
ing fresh JQ1 after 23 hr did not slow fork speeds (Figures 1A and
1B). This suggests that replication forks are rapidly slowed by
JQ1 treatment, but they eventually adapt. Cell cycle distribution
remained unaffected between 1 and 8 hr JQ1 treatment, but cells
accumulated in G1 after 24 hr JQ1 treatment (Figure S1D). The
lack of S-phase arrest could be explained by compensatory
new origin firing (Figure S1E).
To investigate whether ongoing transcription contributes to
JQ1-induced replication slowing, we quantified nascent RNA
synthesis using nuclear incorporation of 5-ethynyluridine (EU)
(Figure 1C). EU incorporation increased by about 35% after
1 hr JQ1 treatment and remained increased up to 72 hr of JQ1
treatment (Figures 1D, 1E, and S1F). Increased RNA synthesis
was also observed in U2OS cells treated with I-BET151 and
in NALM-6 cells (Figures S2A and S2B). For an alternative
approach, we isolated total RNA and normalized yields to cell
numbers, showing that JQ1-treated cells contained more RNA
overall (Figure 1F).
In contrast to our findings, it was previously reported that JQ1
treatment or BRD4 degradation quickly suppress nascent tran-
scription of most protein-coding genes such as MYC, with only
a few genes such as EGR1 and SERTAD1 upregulated (Muhar
et al., 2018; Winter et al., 2017). As previous work focused on
poly-adenylated mRNA sequencing, we decided to investigate
the effect of BET inhibition on non-poly-adenylated RNA spe-
cies. First, we re-analyzed the published RNA Pol II chromatin
immunoprecipitation sequencing (ChIP-seq) datasets (Muhar
et al., 2018). These showed that 1 hr after BRD4 degradation,
genome-wide net occupancy of RNA Pol II actually increased
by 53.8%, particularly over a set of highly transcribed genes
that produce non-poly-adenylated RNAs such as histone and
non-coding RNA genes (Figure S3). We used qRT-PCR to test
whether this increased RNA Pol II occupancy was also
increasing gene expression. Indeed, expression of all selected
candidate genes was also upregulated by JQ1 in U2OS cells
(Figure 1G). Our data support that although BET inhibition sup-
presses transcription of poly-adenylated protein-coding genes,
highly transcribed histone and other non-poly-adenylated non-
coding RNA genes are upregulated, and this may explain the
observed increase in total nascent RNA synthesis.
To test whether replication fork slowing was transcription
dependent, we used short treatments with the transcription in-
hibitors triptolide, DRB, and a-amanitin (Figure 1H). These in-
hibited ongoing RNA synthesis and increased replication fork
speeds specifically in the presence of JQ1 (Figures 1I and 1J).2062 Cell Reports 25, 2061–2069, November 20, 2018Similar results were observed in human non-cancer BJ-hTert fi-
broblasts and in two chronic leukemia cell lines, C2 and MEC1
(Figures S2C–S2H). These data suggest that JQ1-induced repli-
cation stress depends on active RNA synthesis and that this is
not restricted to cancer cells. One hour JQ1 treatment increased
RNA synthesis in four of five cell lines tested, which was always
accompanied by fork slowing (Figure 1K). Fork slowing was
more dramatic in leukemia lines compared with U2OS or fibro-
blasts. Only C2 cells appeared resistant to JQ1 effects, display-
ing neither increased RNA synthesis nor fork slowing.
We used small interfering RNA (siRNA) to investigate which
BET protein was the target of JQ1-induced replication-transcrip-
tion conflicts. We first depleted BRD4, which can interact with
DNA replication proteins (Maruyama et al., 2002; Sansam
et al., 2018; Zhang et al., 2018). BRD4 depletion increased
RNA synthesis (Figures 2A–2D) and reduced fork speeds (Fig-
ure 2E). Adding JQ1 did not further affect fork speeds in
BRD4-depleted cells (Figure 2E). BRD4 siRNA-induced fork
slowing was rescued by ectopic expression of the long isoform
of BRD4 (Figures 2F and 2G) and short transcription inhibitor
treatments (Figure 2H). In contrast, depletion of BRD2 or BRD3
did not increase RNA synthesis and caused negligible fork slow-
ing (Figures 2I–2N). These data suggest that BRD4 is the BET
protein that prevents replication-transcription conflicts and is
required for BET inhibitor-induced replication stress.
We next investigated the mechanism of increased RNA syn-
thesis. It has been shown that both JQ1 and I-BET151 can
disrupt the 7SK-snRP-P-TEFb complex, increasing the propor-
tion of active P-TEFb in complex with the SEC (Bartholomeeusen
et al., 2012; Chaidos et al., 2014). This promotes transcription of
genes including the 7SK-snRP component HEXIM1 (Bartholo-
meeusen et al., 2012). Increased HEXIM1 protein levels eventu-
ally re-establish the 7SK-snRP-pTEFB complex and therefore
P-TEFb inhibition (Figure 3A). We hypothesized that JQ1-
induced replication stress might result from 7SK-snRP dissocia-
tion and increased RNA Pol II activity. In line with this, RNA Pol II
CTD serine2 phosphorylation was transiently increased during
the first hours of JQ1 treatment (Figures 3B and 3C). Several
drugs including hexamethylene bis-acetamide (HMBA) can
dissociate 7SK-snRP from P-TEFb (Fujinaga et al., 2015). If
7SK-snRP dissociation underlies BET inhibitor-induced fork
slowing, then HMBA treatment should also slow replication,
even though HMBA has no known connection to replication
forks. HMBA treatment slightly increased RNA synthesis and
slowed replication forks, which was not further exacerbated by
co-treatment with JQ1 (Figures 3D and 3E). Finally, the short iso-
form of BRD4, which cannot effectively interact with P-TEFb
(Schro¨der et al., 2012), failed to rescue the effect of BRD4 knock-
down on replication fork slowing (Figures 3F–3H).
We decided to further investigate the roles of HEXIM1 in JQ1-
induced RNA synthesis and replication fork slowing. HEXIM1
depletion prevented the early JQ1-induced increase in RNA syn-
thesis and replication fork slowing. After 24 hr JQ1 treatment,
however, RNA synthesis increased, accompanied by fork slow-
ing (Figures 3I–3L). These data suggest that HEXIM1 depletion
delayed the effects of JQ1. Although HEXIM1 protein levels
slowly increased during 48–72 hr JQ1 treatment, there was no
decrease in nascent RNA synthesis (Figures 3J and S1F),
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Figure 1. BET Inhibition Induces Replica-
tion-Transcription Conflicts
(A) DNA fiber labeling in U2OS cells treated
with JQ1.
(B) Replication fork speeds after JQ1 treatment
(n = 3–6).
(C) EU labeling after JQ1 treatment.
(D) Representative images of click-stained EU
labeled cells ± 8 hr JQ1.
(E) Nuclear EU intensities after JQ1 treatment
(n = 3–5).
(F) RNA was extracted after 8 hr JQ1 treatment
and yield normalized to cell number and DMSO
(n = 7).
(G) Fold change in the normalized expression
levels of indicated transcripts ± JQ1 as indicated
(n = 4).
(H) Cells were treated with transcription inhibitors
before and during EU or DNA fiber labeling. AM,
a-amanitin; TRIP, triptolide.
(I) Nuclear EU intensities in cells treated with
transcription inhibitors and JQ1 (n = 4).
(J) Replication fork speeds after 1 hr JQ1 ± tran-
scription inhibitors (n = 3 or 4).
(K) JQ1 effect on nascent RNA synthesis and
replication fork speeds in a panel of human cell
lines.
Data are represented as mean ± SEM. Scale bars,
10 mm. See also Figures S1–S3 and Table S1.
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C Figure 2. Loss of BRD4 Causes Replica-
tion-Transcription Conflicts
(A) DNA fiber labeling after BRD2/3/4 depletion.
(B) Protein levels of BRD4 isoforms after siRNA
depletion. NS, non-specific bands.
(C) Representative EU images ± BRD4 siRNA.
(D) Nuclear EU intensities ± BRD4 siRNA (n = 5).
(E) Replication fork speeds after BRD4 deple-
tion ± 1 hr JQ1 (n = 3).
(F) Equal EmGFP-BRD4 expression 48 hr after
plasmid transfection ± BRD4 siRNA.
(G) Replication fork speeds after BRD4 siRNA ±
BRD4 long isoform expression plasmid (n = 3).
(H) Median replication fork speeds after BRD4
siRNA ± transcription inhibitors (n = 3).
(I) Protein levels of BRD2 after siRNA depletion.
(J) Nuclear EU intensities ± BRD2 siRNA (n = 3).
(K) Replication fork speeds after BRD2 siRNA ±
1 hr JQ1 (n = 3).
(L) Protein levels of BRD3 after siRNA depletion.
NS, non-specific.
(M) Nuclear EU intensities ± BRD3 siRNA (n = 3).
(N) Replication fork speeds after BRD3 siRNA ±
1 hr JQ1 (n = 3).
Data are represented as mean ± SEM. Scale bars,
10 mm.suggesting that the process of replication adaptation is more
complex than a HEXIM1-mediated feedback loop suppressing
transcription.
We then investigated the relationship between JQ1-induced
fork slowing and DNA damage. Replication fork slowing can
expose single-stranded DNA (ssDNA) and, if forks collapse,
cause DSBs. These activate the ATR and ATM checkpoint
kinases and p53. However, JQ1 does not induce DNA dam-
age (Pawar et al., 2018) or activate p53 (Da Costa et al.,
2013). In line with this, we observed no JQ1-induced increase
in ssDNA or DSBs as measured by nuclear foci formation of
RPA and 53BP1 or phosphorylation of the ATM and ATR
targets histone H2AX (gH2AX; Figure 4A), CHK1, and RPA2064 Cell Reports 25, 2061–2069, November 20, 2018(Figure S4A). BRD4 depletion also
failed to induce DNA damage foci
(Figure S4B).
Unexpectedly however, JQ1 induced
foci formation of the homologous recom-
bination factor RAD51, which depended
on ongoing transcription and ATR activity
(Figures 4B–4D and S4C). This sug-
gested that RAD51 is recruited in
response to JQ1-induced transcription-
replication conflicts, aided by basal ATR
activity. We used siRNA to investigate
the impact of RAD51 on replication fork
progression in JQ1-treated cells (Figures
4E and 4F). Interestingly, RAD51 deple-
tion prevented JQ1-induced fork slowing
(Figure 4G). We investigated whether
RAD51 suppresses RNA synthesis, like
HEXIM1. RAD51-depleted cells dis-played high levels of RNA synthesis in both the presence and
absence of JQ1, making these data difficult to interpret (Fig-
ure S4D). Nevertheless, we concluded that RAD51-dependent
rescue of fork speeds was not due to decreased transcription.
Transient overexpression of RAD51 promoted fork slowing after
24 hr JQ1 treatment, additionally supporting that RAD51 directly
slows forks in response to JQ1 (Figures S4E and S4F).
RAD51-mediated fork slowing was previously reported for
DNA-damaging treatments and is suggestive of replication fork
reversal (Zellweger et al., 2015). In support of a fork reversal
model, PARP inhibition and depletion of SMARCAL1 or ZRANB3
(Bhat and Cortez, 2018) also prevented JQ1-induced fork slow-
ing (Figure 4H-J).
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Figure 3. BET Inhibitor-Induced Repli-
cation-Transcription Conflicts Require
HEXIM1
(A) Current model HEXIM1 role in JQ1-induced
transcription increase.
(B) Nuclear immunostaining for phospho-S2 RNA
Pol II ± JQ1.
(C) Nuclear phospho-S2 RNA Pol II intensities as in
(B) (n = 4; n = 2 [24 hr]).
(D) Nuclear EU intensities ± 5 mM HMBA (1 hr)
(n = 3).
(E) Replication fork speeds after HMBA treat-
ment ± JQ1 (1 hr) (n = 3).
(F) Schematic of BRD4 isoforms used.
(G) Protein levels of BRD4 short isoform after full-
length BRD4 siRNA ± BRD4 short isoform
expression plasmid.
(H) Replication fork speeds after full-length BRD4
siRNA ± BRD4 short isoform expression plasmid
(n = 3).
(I) Protein levels of HEXIM1 after 48 hr siRNA
transfection followed by JQ1 for times indicated.
(J) Protein levels of HEXIM1 after 48–72 hr JQ1.
(K) Nuclear EU intensities after HEXIM1 siRNA and
JQ1 treatment (n = 3–9).
(L) Replication fork speeds after HEXIM1 siRNA
and JQ1 treatment (n = 3 or 4, n = 2 [nonT 8 hr]).
Data are represented as mean ± SEM. Scale bars,
10 mm.We then tested the effect of RAD51 depletion on JQ1-induced
DNA damage. Interestingly, RAD51 depletion actually promoted
DNA damage, as indicated by gH2AX and 53BP1 foci formation
(Figures 4K–4M). This suggests that RAD51 prevents DNA dam-
age at JQ1-slowed replication forks.
As HEXIM1 depletion also rescued fork progression, we tested
the effect of HEXIM1 on DNA damage. HEXIM1-depleted cells
accumulated DNA damage early during JQ1 treatment that per-
sisted for 24 hr (Figures 4N and 4O). In line with the increased
DNA damage, HEXIM1-depleted cells were more sensitive to
24 hr JQ1 treatment than control cells, as were ATR inhibitor-
treated cells (Figure S4G). This suggests that both HEXIM1,
which is upstream of transcription-replication conflicts, andCell ReportRAD51, which acts downstream of these
conflicts, contribute to replication fork
slowing and prevent JQ1-induced DNA
damage (Figure 4P).
DISCUSSION
We report that BET inhibition increases
transcription especially of highly tran-
scribed histone and other non-poly-ad-
enylated non-coding RNA genes and
causes transcription-dependent replica-
tion fork slowing. This depends on
HEXIM1, a central factor in the BET inhib-
itor response, and the homologous
recombination factor RAD51, which is
central in the replication stress response.Unusually, BET inhibitor-induced replication stress is transient
and, despite engaging RAD51, does not activate a full DNA dam-
age response. We speculate that these unusual transcription-
replication conflicts will help illuminate some aspects of BET
inhibitor treatment responses.
Our data provide insight into the roles of BRD4 in DNA replica-
tion. Reports show that BRD4 interacts with DNA replication fac-
tors RFC, TICRR, and CDC6 (Maruyama et al., 2002; Sansam
et al., 2018; Zhang et al., 2018). We show here that BRD4 also
regulates DNA replication via its P-TEFb interaction. The BRD4
short isoform contains the interaction domains for TICRR and
RFC (Maruyama et al., 2002; Sansam et al., 2018) but failed to
rescue replication stress. The interaction with CDC6 is not yets 25, 2061–2069, November 20, 2018 2065
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Figure 4. RAD51 and HEXIM1 Modulate BET Inhibitor-Induced DNA Damage
(A) Representative images of DNA damage foci after JQ1 treatment. HU was 2 mM 8 hr.
(B) Representative images of RAD51 foci after JQ1 treatment.
(C) Total percentages (top) and percentage normalized to S/G2 content (bottom) of cells with RAD51 foci after JQ1 treatment (n = 3–6).
(D) Percentages of cells with RAD51 foci ± 4 hr JQ1 and a-amanitin (AM) (n = 3).
(E) EU and DNA fiber labeling after RAD51 depletion.
(legend continued on next page)
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mapped (Zhang et al., 2018). Our data suggest that TICRR and
RFC are not involved in the phenotypes described here. Instead,
they support previous reports that BET inhibition rapidly in-
creases P-TEFb activity (Bartholomeeusen et al., 2012; Chaidos
et al., 2014). We show that this also involves increased RNA syn-
thesis. Our data support that although BET inhibition suppresses
transcription of poly-adenylated protein-coding genes (Muhar
et al., 2018; Winter et al., 2017), non-poly-adenylated RNA
Pol II transcripts such as histones and non-coding RNA genes
are upregulated. We previously reported that overexpression
of H-RASV12 or transcription factor TBP increases nascent
RNA synthesis and causes replication stress (Kotsantis et al.,
2016). BET inhibition shows how small-molecule inhibitor treat-
ments can also cause replication stress by increasing RNA syn-
thesis. Any treatments that disrupt the complex of P-TEFb with
7SK-snRP, including other cancer drugs, such as HDAC inhibi-
tors and azacytidine (Fujinaga et al., 2015), could potentially
cause transcription-replication conflicts in this way.
Our findings suggest that HEXIM1 is required for BET inhibitor-
induced replication fork slowing, which is delayed by at least 8 hr
in the absence of HEXIM1. After 24 hr JQ1, extensive gene
expression changes and possibly HEXIM2 (Byers et al., 2005)
may compensate for HEXIM1 loss. HEXIM1 depletion has been
associated with long-term BET inhibitor resistance. Our findings
do not conflict with this, as BET inhibitor resistance in HEXIM1-
depleted cells was observed only after prolonged (>24 hr) treat-
ment (Devaraj et al., 2016). It was proposed that HEXIM1 loss
counteracts JQ1 by increasing P-TEFb activity (Devaraj et al.,
2016). Importantly, we show that HEXIM1 loss can also promote
JQ1 effects, such as DNA damage. In addition to modulating
transcription-dependent fork slowing, HEXIM1might play undis-
covered roles in replication stress and DNA damage response. It
may be relevant that HEXIM1 also regulates p53 (Lew et al.,
2012). Nevertheless, we observed JQ1-induced replication fork
slowing in a p53 mutant cell line. Reduced HEXIM1 protein
levels have been observed in metastatic breast cancer (Ketchart
et al., 2013), melanoma (Tan et al., 2016), and acute leukemia
(Devaraj et al., 2016; Huang et al., 2016). It will be important for
cancer researchers to further investigate the relationship be-
tween HEXIM1, replication stress, and the response to cancer
treatment.
Homologous recombination capacity of cancer cells is a well-
established predictive biomarker for the response to replication
stress-inducing treatments. RAD51 loading is known to actively
slow forks in response to a variety of genotoxic agents (Zell-(F) Protein levels of RAD51 after siRNA depletion.
(G) Replication fork speeds after 1 hr JQ1 ± RAD51 siRNA (n = 3 and 4).
(H) Replication fork speeds after 1 hr JQ1 ± PARP inhibitor (n = 3).
(I) Protein levels of SMARCAL1 or ZRANB3 48 hr after siRNA transfection.
(J) Replication fork speeds after 4 hr JQ1 ± SMARCAL1 or ZRANB3 siRNA (n = 3
(K) Representative images of gH2AX and 53BP1 foci after JQ1 ± RAD51 siRNA.
(L) Percentages of cells with gH2AX foci after 8 hr JQ1 ± RAD51 siRNA (n = 4).
(M) Percentages of cells with 53BP1 foci after 8 hr JQ1 ± RAD51 siRNA (n = 4).
(N) Percentages of cells with gH2AX foci after JQ1 ± HEXIM1 siRNA (n = 3).
(O) Percentages of cells with 53BP1 foci after JQ1 ± HEXIM1 siRNA (n = 3).
(P) Model: BET inhibition disrupts recruitment of chromatin and replication fac
replication forks without DNA damage.
Data are represented as mean ± SEM. Scale bars, 10 mm. See also Figure S4.weger et al., 2015). We show that BET inhibition also activates
RAD51, likely because of increased transcription, and that
RAD51 promotes fork slowing in response to BET inhibitor,
which may involve fork reversal. Forks may reverse at sites of
direct collisions between replication and transcription machin-
eries or in response to indirect effects of transcription on replica-
tion. RAD51 expression is downregulated in response to BET
inhibition (Yang et al., 2017) and in models of acquired BET
inhibitor resistance (Pawar et al., 2018). Intriguingly, acquired
BET inhibitor resistance models also displayed increased
DNA damage signaling (Pawar et al., 2018). This agrees with
our data that RAD51 downregulation increases DNA damage
signaling.
Our data support a speculativemodel whereby loss of HEXIM1
or RAD51 allows normal replication fork progression in the pres-
ence of BET inhibitor at the expense of DNA damage. This may
even contribute to long-term BET inhibitor resistance. Although
it is extensively documented that transcription-replication con-
flicts promote DNA damage, BET inhibition seems to induce
DNA damage when such conflicts are prevented. This latter
damage might, for example, result from reduced chromatin
recruitment of chromatin remodelers (Floyd et al., 2013) or
DNA replication proteins (Sansam et al., 2018; Zhang et al.,
2018) (Figure 4P). The underlying mechanisms, and how they
relate to BET inhibitor response, will require future investigation.
In summary, we provide insights into the relationship amongBET
proteins, DNA replication, and DNA damage response that will
be relevant to cancer therapy research.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rat monoclonal anti-BrdU [BU1/75] Abcam Cat# ab6326, RRID:AB_305426
Mouse monoclonal anti-BrdU [B44] Becton Dickinson Cat# 347580, RRID:AB_10015219
Mouse monoclonal anti-phospho-Histone
H2AX (Ser139) [JBW301]
Millipore Cat# 05-636, RRID:AB_309864
Rabbit polyclonal anti-53BP1 Bethyl A300-272A, RRID:AB_185520
Mouse monoclonal anti-RNA Pol II pS2 [H5] Abcam at# ab24758, RRID:AB_2167352
Mouse monoclonal anti-RPA32 [RPA34-19] Merck Cat# NA18-100UG, RRID:AB_213121
Rabbit polyclonal anti-RAD51 Abcam Cat# ab63801, RRID:AB_1142428
Rabbit monoclonal anti-BRD2 [EPR7642] Abcam Cat# ab139690, RRID:AB_2737409
Rabbit polyclonal anti-BRD3 Abcam Cat# ab83478, RRID:AB_1860012
Rabbit monoclonal anti-BRD4 [EPR5150(2)] Abcam Cat# ab128874, RRID:AB_11145462
Rabbit polyclonal anti-HEXIM1 Abcam Cat# ab25388, RRID:AB_2233058
Rabbit polyclonal anti-pS4/S8 RPA32 Bethyl Cat# A300-245A, RRID:AB_210547
Rabbit polyclonal anti-pS317 CHK1 Cell Signaling Cat# 2344, RRID:AB_331488
Mouse monoclonal anti-PARP1 [F-2] Santa Cruz Cat# sc-8007, RRID:AB_628105
Rabbit polyclonal anti-ZRANB3 Proteintech Cat# 23111-1-AP RRID:AB_2744527
Mouse monoclonal anti-SMARCAL1 [A-2] Santa Cruz Cat# sc-376377 RRID:AB_10987841
Mouse monoclonal anti-aTUBULIN [B512] Sigma Cat# T6074, RRID:AB_477582
Rabbit polyclonal anti-bACTIN Cell Signaling Cat# 4967, RRID:AB_330288
Chemicals, Peptides, and Recombinant Proteins
(+)-JQ1 Tocris 4499/10
I-BET151 Tocris 4650/10
AZ20 Tocris 5198/10
Olaparib Selleckchem S1060
Triptolide Tocris 3253/1
DRB Sigma D1916
alpha-Amanitin Sigma A2263
Hydroxyurea Sigma H8627
Critical Commercial Assays
Click-iT RNA Alexa Fluor 594 Imaging Kit Thermo Fisher C10330
RNeasy Mini Kit QIAGEN 74104
miRNeasy Mini Kit QIAGEN 217004
SuperScript III Reverse Transcriptase Thermo Fisher 18080093
SensiFAST SYBR Lo-ROX Kit Bioline BIO-94005
Deposited Data
Gene Expression Omnibus Series GSE111463 Muhar et al., 2018 https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE111463
Experimental Models: Cell Lines
U2OS ATCC Cat# HTB-96, RRID:CVCL_0042
BJ-hTert ATCC Cat# CRL-4001, RRID:CVCL_6573
NALM-6 DSMZ Cat# ACC-128, RRID:CVCL_0092
C2 DSMZ Cat# ACC-773, RRID:CVCL_0D73
MEC1 DSMZ Cat# ACC-497, RRID:CVCL_1870
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Oligonucleotides
BRD2 ON-TARGETplus SMARTpool - Human Dharmacon L-004935-00
BRD3 ON-TARGETplus SMARTpool - Human Dharmacon L-004936-00
BRD4 ON-TARGETplus SMARTpool - Human Dharmacon L-004937-00
HEXIM1 ON-TARGETplus SMARTpool - Human Dharmacon L-012225-01
RAD51 siRNA, targeting sequence
50-GAGCUUGACAAACUACUUC-30
Ito et al., 2005 n/a
ZRANB3 individual siGENOME siRNA Dharmacon D-010025-03
SMARCAL1 siRNA Dharmacon L-013058-00
Allstars negative control siRNA QIAGEN SI03650318
See Table S1 for qRT-PCR primers n/a n/a
Recombinant DNA
pcDNA6.2/N-EmGFP-BRD4(long)-DEST Philpott et al., 2014 n/a
pCDNA5-3HA-BRD4(short)-DEST Gift from Panagis
Fillipakopoulos
n/a
pcDNA3.1/V5/His-TOPO-RAD51 Sørensen et al., 2005 n/a
pcDNA3.1(+) ThermoFisher V79020
pEGFP-C2 Clontech 6083-1
Software and Algorithms
ImageJ n/a https://imagej.nih.gov/ij/
ENCODE tools n/a https://www.encodeproject.org/software/
wigtobigwig/
deepTools n/a http://deeptools.ie-freiburg.mpg.de/
Integrative Genomics Viewer n/a https://software.broadinstitute.org/software/igv/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Eva Pe-
termann (e.petermann@bham.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human U2OS, NALM-6, C2, MEC1 and BJ-hTert cells (ATCC) were authenticated using 8-locus STR profiling (LGC Standards). Cells
were confirmed Mycoplasma free and grown in DMEM (high glucose) or RPMI 1640 in a humidified atmosphere containing 5%CO2.
METHOD DETAILS
Drug treatments
JQ1 (1 mM), I-BET151 (1 mM), AZ20 (2.4 mM), and triptolide (1 mM) were from Tocris Bioscience. Olaparib (5 mM) was from Selleck-
chem. 5,6-dichloro-1-b-D-ribofuranosyl-1H-benzimidazole (DRB, 100 mM), a-amanitin (10 mg/ml), and hydroxyurea (2 mM) were
from Sigma.
DNA fiber analysis
Cells were labeled with 25 mMCldU and 250 mM IdU for 20min each and DNA fiber spreads prepared. HCl-treated fiber spreads were
incubated with rat anti-BrdU (BU1/75, Abcam ab6326, 1:250) and mouse anti-BrdU (B44, Becton Dickinson 347580, 1:500) for 1 h,
fixed with 4% PFA and incubated with anti-rat AlexaFluor 555 and anti-mouse AlexaFluor 488 (Thermo Fisher) for 1.5 h.
EU incorporation assay
5-ethynyl uridine (EU) incorporation assays were performed using the Click-iT RNA Alexa Fluor 594 Imaging Kit (Thermo Fisher). Cells
were incubated with 1 mM EU for 1 h, followed by fixation and Click reaction according to manufacturer’s instructions. DNA was
counterstained with DAPI. Imaging was performed immediately after Click reaction and nuclear masks were generated in ImageJCell Reports 25, 2061–2069.e1–e4, November 20, 2018 e2
to quantify mean fluorescence intensities per nucleus. Results were normalized to control/DMSO to account for variation in staining
intensity.
siRNA and DNA transfection
siRNAs against BRD2, BRD3, BRD4, HEXIM1, SMARCAL1, ZRANB3, (L-004935-00, L-004936-00, L-004937-00, L-012225-01,
L-013058-00, D-010025-03), and RAD51 (Ito et al., 2005), were from Dharmacon, and ‘‘Allstars negative control siRNA’’ from
QIAGEN. Cells were transfected with 50 nM siRNA using Dharmafect 1 reagent (Dharmacon). For BRD4 and RAD51 overexpression
cells were transfected using TransIT-2020 (Mirus Bio) with 2.5 mg pcDNA6.2/N-EmGFP-BRD4(long)-DEST (Philpott et al., 2014),
pCDNA5-3HA-BRD4(short)-DEST (kind gift from Dr Panagis Filippakopoulos), pcDNA3.1/V5/His-TOPO-RAD51 (Sørensen et al.,
2005), or control plasmids pcDNA3.1(+) (Thermo Fisher) or pEGFP-C2 (Clontech).
Immunofluorescence
Cells were fixed with 4% PFA for 10 min, permeabilised with 0.25% Triton X-100 for 5 min, and blocked with 2% BSA. Primary an-
tibodies were mouse anti-phospho-Histone H2AX (Ser139) (JBW301, Millipore 05-636, 1:1000), rabbit anti-53BP1 (Bethyl A300-
272A, 1:30000), mouse anti-RNA Pol II pS2 (Abcam ab24758, 1:500,), mouse anti-RPA32 (Merck NA18, 1:500) and rabbit anti-
RAD51 (Abcam ab63801, 1:500). Secondary antibodies were anti-mouse IgG AlexaFluor 488 and anti-rabbit IgG AlexaFluor 555
(Thermo Fisher). DNA was counterstained with DAPI and images were acquired on a Nikon E600 microscope with a Nikon Plan
Apo 60x (1.3 NA) oil lens, a Hamamatsu digital camera (C4742-95) and the Volocity acquisition software (Perkin Elmer). Images
were analyzed using ImageJ. Cells with more than 5 RAD51 foci and 8 gH2AX or 53BP1 foci were scored as positive. Scale bars
are 10 mm.
Western blotting
Cell extracts were prepared in UTB buffer (50 mM Tris-HCl pH 7.5, 150 mM b-mercaptoethanol, 8 M urea) and sonicated to release
DNA-bound proteins. Primary antibodies used were rabbit anti-BRD2 (Abcam ab139690, 1:1000), rabbit anti-BRD3 (Abcam
ab83478, 1:500), rabbit anti-BRD4 (Abcam ab128874, 1:1000), rabbit anti-HEXIM1 (Abcam ab25388,1:5000), rabbit anti-pS4/S8
RPA32 (Bethyl A300-245A, 1:1000), rabbit anti-pS317 CHK1 (Cell Signaling 2344, 1:1000), rabbit anti-RAD51 (Abcam, ab63801,
1:1000) mouse anti-PARP1 (Santa Cruz sc8007, 1:1000), rabbit anti-ZRANB3 (Proteintech 23111-1-AP, 1:500), mouse anti-
SMARCAL1 (Santa Cruz sc-376377, 1:15,000), mouse anti-aTUBULIN (B512, Sigma T6074, 1:10000), rabbit anti-bACTIN (Cell
Signaling 4967, 1:5000).
RNA isolation
Cells were harvested and counted, and RNA was isolated using the QIAGEN RNeasy Mini Kit according to manufacturer’s instruc-
tions. RNA concentration was determined using an Implen NanoPhotometer Pearl and normalized to cell numbers.
Next-generation sequencing data analysis
The available bigwig RNA Pol II ChIP-Seq files were downloaded and analyzed using ENCODE tools (https://www.encodeproject.
org/software/wigtobigwig/) and deepTools (http://deeptools.ie-freiburg.mpg.de/) to obtain files for the quantification analysis. To
identify genes with more RNA Pol II in the dataset (IAA versus DMSO), average scores in every genomic region were calculated
for each bigWig file using deepTools. The Integrative Genomics Viewer (IGV) snapshots were generated loading the respective bigwig
files on IGV, while the difference between the coverages was generated using igvtools/combine tracks.
Quantitative RT-PCR
Total RNA was harvested using the miRNeasy Mini Kit (QIAGEN) followed by DNase I treatment (Roche). 1 mg of total RNA was
reverse-transcribed using SuperScript Reverse Transcriptase III (ThermoFisher) with random primers (Promega), following manufac-
turer’s instructions. The qPCR primers for amplification are listed in Table S1. For quantitative RT-PCR, 2 ml of cDNA were analyzed
using a CFX Connect real-time PCRmachine (BioRad) with SensiFAST SYBR Lo-ROX Kit (Bioline). Cycling parameters were 95C for
3min, followed by 40 cycles of 95C for 10 s, 60C for 30 s. Result were normalized to RPLP0, whichwe have found to be a very stable
transcript. DcT was calculated as difference in the cycle threshold of the transcript of interest and RPLP0, plotted as fold change
compared to the CTR untreated sample.
Colony survival assay
Defined numbers of cells were plated in duplicate before treatment with JQ1 (1 – 30 mM) for 24 h. Colonies of > 50 cells were allowed
to form in fresh medium and fixed in 50% ethanol, 2% methylene blue.
Flow cytometry
Cells were fixedwith cold 70%ethanol before staining with 10 mg/ml propidium iodide. Cell cycle profiles were gathered using the BD
LSR Fortessa X20 and analyzed with BD FacsDiva software.e3 Cell Reports 25, 2061–2069.e1–e4, November 20, 2018
QUANTIFICATION AND STATISTICAL ANALYSIS
Values represent the means ± 1x SEM of independent biological repeats. For DNA fiber analysis, at least 100 fibers from 10 different
areas were measured and the median of the distribution was calculated for each independent biological repeat. For foci and EU
analysis, at least 10 different areas were quantified for each independent biological repeat. The number of independent biological
repeats (n) is indicated in the figure legends. The statistical test used throughout was the one-tailed Student’s t test except for colony
assays, where 2-way ANOVA with Tukey’s was calculated using GraphPad Prism 6, as indicated in the figure legends. Asterisks
compare to control, unless indicated otherwise in the figure panels, and signify *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
DATA AND SOFTWARE AVAILABILITY
This study analyzed published next generation sequencing data (Muhar et al., 2018). The accession number for these data is GEO:
GSE111463.Cell Reports 25, 2061–2069.e1–e4, November 20, 2018 e4
